Steroid hormones play key roles in regulating cell proliferation and dierentiation in targeting tissues. However, in advanced cancers, the steroid hormone regulation is frequently attenuated through a yet unknown mechanism even in the presence of functional steroid hormone receptors. We investigate the functional role of tyrosine phosphorylation signaling in the hormone-refractory growth of human prostate tumors. Initial studies demonstrate that the androgen-responsive phenotype of human prostate cancer cells associates with a low phosphotyrosine (p-Tyr) level of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine phosphatase. In prostate cancer cells, the p-Tyr level, but not the protein level, of ErbB-2 inversely correlates with the androgen-responsiveness of cell proliferation. Androgen-stimulated cell growth concurs with a down-regulation of cellular PAcP, an elevated p-Tyr level of ErbB-2, and the activation of mitogen-activated protein kinases. Furthermore, only the ErbB-2 inhibitor AG 879, but not the EGFR inhibitor AG 1478, abolishes androgen-induced cell proliferation. Forced expression of ErbB-2 can also attenuate androgen promotion of cell growth. Data taken collectively conclude that in human prostate cancer cells, the tyrosine phosphorylation of ErbB-2 regulated by cellular PAcP plays a key role in regulating androgen-mediated proliferation signaling.
Introduction
Steroid hormone receptors are transcriptional factors in a large family known as the steroid/thyroid receptor superfamily. Upon binding of hormone, the receptor undergoes a conformational change, which prompts the transcriptional activity of receptor on genomes (Jensen, 1991; Bagchi et al., 1992) . The ligand-dependent action of steroid hormone receptors is involved in regulating numerous cellular activities including cell proliferation of target organs. It is shown that the production and secretion of peptide growth factors can be controlled by steroid hormone (Dickson and Lippman, 1987; Liu et al., 1993) . The expression level of growth factor receptors could also be modulated by steroid hormone (Fanger et al., 1984; Murphy et al., 1986; Brass et al., 1995) . The fundamental of steroid-mediated cell proliferation, however, is not yet completely known.
Androgen receptor is a member of steroid hormone superfamily. Its ligands, androgens, regulate the development and maintenance of dierentiated function of male reproductive organs (Yan et al., 1992; Sadi and Barrack, 1993; Yuan et al., 1993) including prostate (Tenniswood, 1986) . The normal prostate gland depends on androgen for development and functional integrity (Sandberg and Kadohama, 1980) ; while upon prostate carcinogenesis, advanced cancer cells underlie a transition from the androgen-responsive to androgen-unresponsive stage (Scott et al., 1980) . This phenomenon occurs spontaneously in patients under hormonal manipulation, including anti-androgen and androgendeprivation therapies (Grayhack et al., 1987; Gittes, 1991) . The steroid hormone-resistant phenotype is also seen in cancers originated from other hormone-responsive organs, including human breast (Glauber and Kiang, 1992) , ovary (Hua et al., 1995) and lymphoid (Weiss et al., 1990) . Although epigenetic alterations have been proposed, details of this development remain largely unknown. It is possible that a dierential expression of key modulators of steroid action is involved in this progression. Thus, an extensive study is needed for understanding the molecular mechanism of this transition. This knowledge would not only reveal signal transduction pathways by which steroid hormones regulate cell proliferation but also provide an insight for developing novel therapeutic strategies of these cancers including prostate.
The steroid hormone receptor is required in mediating the action of corresponding steroid hormone in target cells (Tjian and Maniatis, 1994; Quigley et al., 1995; Beato and Sanchez Pacheco, 1996) . Therefore, it is proposed that the loss of androgen-responsiveness in advanced human prostate cancer cells is due to lacking the expression of androgen receptor (AR). Experiments using Dunning rat prostate cancer cell lines as a model system demonstrate that a decreased AR expression correlates with a diminution of androgen action in these cells (Isaacs, 1982; Diamond and Barrack, 1984; Quarmby et al., 1990) . Data from human clinical studies, however, show that most cancers with an androgen-unresponsive phenotype express a high level of AR (Taplin et al., 1995) , and prostate speci®c antigen (PSA) (Stamey et al., 1989; Miller et al., 1992) whose expression is up-regulated by the functional AR in prostate cells. Similar phenomena are observed in estrogen receptor-positive human breast (Glauber and Kiang, 1992) and ovarian cancers (Hua et al., 1995) , and also in glucocorticoid hormone receptor-positive lymphoma (Weiss et al., 1990) , in which cancer cells are growth-resistant to corresponding steroid hormones and antagonists.
Tyrosine phosphorylation signaling plays an important role in regulating proliferation and dierentiation of human normal and cancer cells (Cantley et al., 1991; Cross and Dexter, 1991) . A hyper-tyrosine phosphorylation on cellular proteins, which could be due to either the activation of tyrosine kinases or the inactivation of tyrosine phosphatase or both, has been shown to stimulate cell proliferation and neoplastic transformation (Hunter and Sefton, 1980; Hunter, 1995) . In the case of human breast cancer, it is seen that ErbB-2 protein, a member of the erbB receptor tyrosine kinase (RTK) family, is overexpressed by its gene ampli®cation in one third of patients (Slamon et al., 1989; Harris et al., 1992; Press et al., 1993) . Studies further demonstrate an association between the overexpression of ErbB-2 and the growth-unresponsiveness to estrogens and antiestrogens in ovarian and breast cancer cells (Nicholson et al., 1990; Wright et al., 1992; Hua et al., 1995; Pietras et al., 1995) . These data imply that an elevated erbB tyrosine kinase activity can lead to the steroid hormoneindependency in those cancer cells. However, studies using clinical archival prostate carcinomas have clearly shown that there is no overexpression of ErbB-2 in primary prostate carcinomas including those in the advanced stages, which are normally androgen-unresponsive (Macoska et al., 1992; Kuhn et al., 1993; Sadasivan et al., 1993; Latil et al., 1994; Strohmeyer and Slamon, 1994; Gu et al., 1996; Arai et al., 1997) .
Previous investigations have clearly shown that a human prostate epithelium-speci®c protein tyrosine phosphatase (PTP), prostatic acid phosphatase (PAcP), has a high level of expression in noncancerous prostate tissues (Reif et al., 1973; Foti et al., 1977; Loor et al., 1981) . The expression level of cellular PAcP is decreased signi®cantly in the advanced stage of prostate carcinomas (Reif et al., 1973; Lin and Clinton, 1987) . Among dierent human prostate cancer cell lines, androgen-responsive cells express cellular PAcP, but the unresponsive cells do not . Interestingly, upon the progression from androgensensitive to androgen-insensitive phenotype, cancer cells lose PAcP expression and have highly tyrosine phosphorylated cellular proteins (Lin et al., 1992 . Conversely, forced expression of cellular PAcP restores the androgen-responsive phenotype in transfected cells . Our data further show that PAcP regulates the phosphotyrosine (p-Tyr) level of ErbB-2 (Lin and Meng, 1996; Meng and Lin, 1998) . We therefore postulate that a decreased cellular PAcP expression results in a highly tyrosine phosphorylated ErbB-2, which subsequently initiates constitutively active proliferation signals, leading to the androgenindependent phenotype of advanced prostate cancer. To test this hypothesis, we investigate the molecular mechanism of androgen-responsiveness using our cell culture model. The results clearly show that the p-Tyr dephosphorylation of ErbB-2 by cellular PAcP is evidently required for obtaining the phenotype of androgen-responsiveness in AR-positive human prostate cancer cells.
Results
Dephosphorylation of ErbB-2 by PAcP concurs with androgen responsive proliferation of prostate cancer cells
We established dierent sublines of LNCaP cells by continuously passaging cells in culture . C-81 LNCaP cells had a low level of cellular PAcP that correlated with a rapid growth rate and an androgenunresponsive phenotype ( Figure 1a) ; in contrast to the slow-growing, androgen-responsive C-33 cells, which expressed a high level of PAcP (Figure 1a) . By transfection of PAcP cDNA into C-81 cells, the androgen-responsive phenotype was restored, as observed in two transfectants, . To investigate the molecular mechanism by which cells become androgen-unresponsive, we analysed levels of AR and erbB RTKs in these cells. Results from immunoblotting analyses revealed that dierent subcloned LNCaP cells expressed a similar level of AR and ErbB-2 proteins (Figure 1b) . Hormone-unresponsive C-81 and LN-CMV cells exhibited a higher level of EGFR than hormone-responsive C-33, LN-28 and LN-40 cells (Figure 1b) . However, no correlation between the androgen-sensitivity and the amount of ErbB-3 was seen (Figure 1b ). When the tyrosine phosphorylation level of erbB members was further examined, we observed that EGFR was only marginally phosphorylated in all clones, despite their dierent hormone-sensitivity ( Figure 1c) . Interestingly, the ErbB-2 protein in C-81 and LN-CMV androgen-unresponsive cells was highly phosphorylated (Figure 1c ), corresponding to their low expression level of cellular PAcP and rapid proliferation rate (Figure 1a ). The p-Tyr level of ErbB-3 was elevated not only in C-81 and LN-CMV cells but also in C-33 LNCaP cells ( Figure  1c ). It should be noted that ErbB-3 protein in LNCaP cells is expressed as a doublet, similar to that reported previously (Beerli and Hynes, 1996; Graus Porta et al., 1997) . Only the isoform with a higher molecular weight is tyrosine phosphorylated (Figure 1c ).
PC-3 cells which express a marginal level of functional AR but do not express endogenous PAcP were utilized to further examine the molecular mechanism. As shown in Figure 2a , cDNA transfection of PAcP in PC-3 cells resulted in a decreased growth rate and an androgen-promoted cell growth of three stable transfectants, i.e., PC-411, -412 and -416. All PC-3 parental and transfected cells expressed a low, but detectable, level of AR protein (Figure 2b ). The EGFR expression was independent of androgen-sensitivity of these cells, whereas ErbB-3 had a high level of expression only in the hormone-insensitive PC-3 parental cells (Figure 2b ). Similar to LNCaP cells, the ErbB-2 protein level among dierent subclones of PC-3 was essentially the same (Figure 2b) . Furthermore, consistent with the observation in LNCaP cells, ErbB-2 was highly phosphorylated in androgen-unresponsive PC-3 cells (Figure 2c ). In contrast, the PC-416 transfectant, which is the most sensitive subclone to androgen (Figure 2a) , had the lowest tyrosine phosphorylation level on ErbB-2 ( Figure 2c ). There was no correlation between the degree of hormone-responsiveness of cell growth and p-Tyr status of EGFR or ErbB-3 among PC-3 subclones (Figure 2a vs c) . Thus, the tyrosine phosphorylation of ErbB-2, which is modulated by cellular PAcP, might be a key factor that regulates the androgen-responsiveness of human prostate cancer cells.
Androgen induces tyrosine phosphorylation of ErbB-2 in hormone-responsive human prostate cancer cells
The functional role of ErbB-2 in regulating androgenstimulated cell growth was further examined. We analysed its tyrosine phosphorylation status in cells exposed to androgen. As shown in Figure 3 , DHT treatment resulted in an increased tyrosine phosphorylation of ErbB-2 and a decreased cellular PAcP protein level in androgen-responsive C-33 LNCaP, LN-28, and LN-40 cells in a dose-dependent fashion (Figure 3a) . Similarly, DHT could cause an increased p-Tyr in ErbB-2 (Figure 3b) , and a decreased cellular PAcP activity in PC-412 and PC-416 cells (data not shown). However, androgen has no obvious eect on inducing the p-Tyr level of ErbB-2 (Figure 3a) or decreasing the cellular PAcP protein level in C-81 LNCaP cells (data not shown). This could be due to a low basal level of PAcP in C-81 LNCaP cells ( Figure  1a) . Nevertheless, androgen treatment even results in a 5 cells/well in a medium containing 5% FBS in six-well plates for 3 days. Cells were then grown in a steroid hormone-reduced medium with 2% charcoal-treated FBS for 2 days before exposed to 10 78 M DHT. After 7 days of androgen exposure, cells were harvested, counted and lysed. The relative cell growth was represented by the ratio of cell number normalized to that of C-33 LNCaP cells grown in medium without androgen (top). The data shown are the average from duplicate wells. Similar results were observed in three sets of independent experiments. Bar, the range of results from duplicate wells. PAcP expression in each control sample (without DHT treatment) of LNCaP sublines was visualized by immunoblotting method (bottom). (b) Subcon¯uent LNCaP sublines grown in a 2% charcoal-treated FBS-containing medium were harvested and lysed. Total lysates were analysed for the levels of AR, EGFR, ErbB-2 and ErbB-3 by immunoblotting using speci®c Abs of NH-27, 1005, C-18 and C-17, respectively. (c) 1 mg of total lysates from sublines of LNCaP cells, as described in b, were reacted with 5 mg of anti-EGFR (R-1), anti-ErbB-2 (9G6), and anti-ErbB-3 (C-17) Abs, respectively. The immunoprecipitated proteins were analysed by immunoblotting with 4G10 anti-p-Tyr Ab (pY, top in each case), subsequently with the Ab against the speci®c protein (1005 for EGFR, K-15 for ErbB-2 and C-17 for ErbB-3; bottom in each case). Two forms of ErbB-3 protein with dierent molecular weights were precipitated by C-17 Ab, as indicated by arrows. IP: immunoprecipitation decreased p-Tyr level of c-ErbB-2 in PC-3 parental cells ( Figure 3b ). These data indicate that in androgenunresponsive human prostate cancer cells, ErbB-2 proteins are constitutively hyper-tyrosine phosphorylated (Figures 1 and 2 ), and cannot be further stimulated by adding DHT. In contrast, the basal pTyr level of ErbB-2 in androgen-responsive cells is low (Figures 1 and 2 ). DHT down-regulates cellular PAcP and induces an enhanced tyrosine phosphorylation of ErbB-2 (Figure 3 ), resulting in an increased proliferation rate of these cells (Figures 1 and 2 ).
Time course reveals a decreased cellular PAcP expression prior to the induction of tyrosine phosphorylation on ErbB-2 and the activation of MAP kinase by androgen Our observations in androgen induction of tyrosine phosphorylation on ErbB-2 protein were after 72 h of treatment in hormone-responsive cancer cells ( Figure   3 ). We explored this induction by DHT with a time course study. C-33 LNCaP cells were exposed to 10 78 M DHT. Total cellular lysates were isolated at 0, 3, 6, 12, 24 and 48 h time points and ErbB-2 protein was immunoprecipitated to analyse its p-Tyr status. Surprisingly, the elevated p-Tyr level of ErbB-2 appeared only after 48 h of androgen treatment ( Figure 4a ). We further examined the activity of mitogen-activated protein (MAP) kinase in DHTtreated cells since this kinase can transduce the proliferating and oncogenic signals of ErbB-2 (Ben- Levy et al., 1994; Janes et al., 1994) . Interestingly, androgen-activation of MAP kinase required a 48 h treatment to induce its Thr/Tyr phosphorylation (Figure 4b ), following a similar time course of the activation on ErbB-2 ( Figure 4a) . Furthermore, as shown in Figure 4c , in the presence of androgen, cellular PAcP declined prior to the elevation of tyrosine phosphorylation on ErbB-2. At the 48 h time Figure 1 . After 7 days of androgen exposure, cells were harvested, counted, and lysed. The relative cell growth was represented by the ratio of cell number normalized to that of parental PC-3 cells growing in a medium without androgen (top). The data shown are the average from duplicate wells. Similar results were observed in three sets of independent experiments. *P50.05 versus control cells (n=6). **P50.01 versus control cells (n=6). Bar: the range of results from duplicate wells. PAcP expression in control samples (without DHT treatment) of all sublines of PC-3 cells was visualized by immunoblotting (bottom). (b) Subcon¯uent PC-3 sublines grown in a 2% charcoal treated FBScontaining medium were harvested and lysed. Total lysates were analysed for the level of AR, EGFR, ErbB-2 and ErbB-3 by immunoblotting using speci®c Abs. (c) 1 mg of total lysates from sublines of PC-3 cells, as described in b, were reacted with 5 mg of anti-EGFR, anti-ErbB-2, and anti-ErbB-3 Abs, respectively. The immunoprecipitated proteins were analysed by immunoblotting with antip-Tyr Ab (pY, top), subsequently with the Ab against the speci®c protein (bottom). IP: immunoprecipitation point, the highly phosphorylated ErbB-2 and MAP kinase proteins corresponded to a very low level of cellular PAcP in C-33 LNCaP cells (Figure 4a ,b vs c). Thus, in the androgen-promoted cell growth, the decreased cellular PAcP expression precedes the activation of ErbB-2-mediated signaling pathway.
Neither EGFR nor ErbB-3 is regulated consistently by androgen in hormone-responsive cancer cells
We investigated the eect of androgen on regulating the p-Tyr status of EGFR and ErbB-3 in C-33 LNCaP cells since this is the only cell line among those studied that demonstrates an endogenous capacity for growth response to androgen. As shown in Figure 5a ,b, DHT did not induce tyrosine phosphorylation on EGFR or ErbB-3. A slightly increased p-Tyr signal of EGFR in androgen-treated cells was apparently due to an elevated protein expression (Figure 5a ).
It was proposed that in hormone-responsive human prostate cells, an increased EGFR expression is responsible for executing the androgen-induced proliferating signal (Schuurmans et al., 1991; Brass et al., 1995) . We examined this hypothesis further. As shown in Figure 5c , DHT induced the protein expression of EGFR in C-33 LNCaP cells in a dose-dependent manner, corresponding to the DHT-stimulated cell growth (Figure 1a) . However, DHT does not alter the EGFR level in other androgen-responsive cells (LN-28 and LN-40 in Figure 5c ; PC-412 and PC-416 in Figure  5d ), suggesting that the re-introduction of PAcP in clone-81 LNCaP cells may only restore their partial androgen-responsiveness. Furthermore, although DHT can up-regulate EGFR expression in PC-3 cells (Figure  5d ), the increase in EGFR does not lead to an increased growth rate (Figure 2a) . These results indicate that neither the level nor the tyrosine phosphorylation of EGFR and ErbB-3 is consistently correlated with androgen-promoted proliferation in human prostate cancer cells.
Tyrphostin AG 879, but not AG 1478, abolishes androgen-stimulated cell growth in C-33 LNCaP cells
To further analyse the role of EGFR and ErbB-2 in mediating androgen signaling, RTK inhibitors were 6 cells/T75¯ask in a 5% FBS-containing medium. Three days after plating, cultured medium was replaced with a phenol red-free RPMI 1640 medium containing 2% charcoal-treated FBS. Subsequently cells were cultured for two more days before exposed to 0, 10 79 or 10 78 M of DHT for 72 h. Cells then were harvested and lysed. 1 mg of total lysates from sublines of LNCaP cells (a), or sublines of PC-3 cells (b) was reacted with 5 mg of 9G6 Ab to immunoprecipitate ErbB-2 proteins, which were analysed by immunoblotting with anti-p-Tyr Ab (pY, top), subsequently with anti-ErbB-2 Ab (bottom). The relative p-Tyr level of ErbB-2 was semiquanti®ed by normalizing to its protein level after densitometric analyses. IP: immunoprecipitation utilized. We chose C-33 LNCaP cells as the model because only this cell line showed a correlation between androgen-responsiveness and EGFR activation ( Figure  5c ). Cells were exposed to ErbB-2 inhibitor (AG 879), or EGFR inhibitor (AG 1478) in the absence or presence of DHT, respectively. AG 1478 at 30 nM, a concentration 10-fold higher than the IC 50 (for review, see Levitzki and Gazit, 1995) , was the lowest dosage used. However, due to the potent cytotoxicity of AG 879 to LNCaP cells (data not shown), the lowest dosage was 0.1 mM, which is one-tenth of IC 50 (Levitzki and Gazit, 1995) . We observed that AG 879 eectively blocks basal and DHT-induced tyrosine phosphorylation of ErbB-2 (Figure 6a , top panel). Both basal proliferation and androgen-responsive growth were suppressed by AG 879 in a dose-response fashion (Figure 6a, bottom panel) . AG 879 at 0.5 mM could completely block the DHT-stimulated cell growth (Figure 6a, bottom panel) . In contrast to the eect on ErbB-2, DHT only induced a marginal increase of p-Tyr level on EGFR (Figure 6b, top panel) . However, this phosphorylation could be fully inhibited by AG 1478 (Figure 6b , top panel). AG 1478 also completely blocked EGF-stimulated phosphorylation of EGFR (Figure 6b , top panel), but had no signi®cant eect on the cell proliferation even with a concentration up to 1000-fold of IC 50 , whether in the absence or presence of DHT (Figure 6b, bottom panel) . These results clearly show that the activity of ErbB-2, but not EGFR, is required in mediating androgen-induced proliferating signals in human prostate cancer cells.
Overexpression of ErbB-2 promotes cell growth and diminishes androgen effectiveness of growth stimulation Data taken collectively suggest that the activation of ErbB-2-directed tyrosine phosphorylation signaling converts the phenotype of human prostate cancer cells from androgen-responsiveness to androgen-unresponsiveness (Figures 1 ± 6 ). To test this hypothesis, we examined whether an increased level of ErbB-2 protein as a result of exogenous gene expression can lead to the androgen-insensitivity of C-33 LNCaP cells. Transient transfection with c-erbB-2 cDNA driven by a CMV promoter was utilized in this study. As shown in Figure 7a , on day 0, which was 48 h after transfection and the time point for adding androgen to culture media, an overexpression of ErbB-2 correlated with a high p-Tyr level of pp185 (arrow) in transfected cells. We used pp185 to represent tyrosine phosphorylated ErbB-2 protein since the immunodepletion experiment demonstrated that ErbB-2 is the major phosphoprotein at the 185 kDa position when total lysates of LNCaP cells were separated on SDS ± PAGE (Meng and . Immunoblotting with anti-Myc antibody further revealed the expression of exogenous ErbB-2 proteins (Figure 7a) , which was fused with Myc and 6x His tags (see Materials and methods). Androgen treatment caused an increased tyrosine phosphorylation of pp185 in 3.1A vector-transfected cells on days 3 and 5 (Figure 7a) , consistent with the induction of cell proliferation by DHT (Figure 7b ). Due to the overexpression of ErbB-2 proteins in transfectants, the tyrosine phosphorylation level of pp185 was higher than that in the corresponding control cells (Figure 7a ), correlating with a rapid basal growth rate (Figure 7b) . Interestingly, exogenous ErbB-2 eectively reduced the magnitude of androgen-stimulated cell growth. As shown in Figure 7b , the degree of DHT-promoted proliferation in ErbB-2 transfectants was 50% of that in control cells on day 3, and only 30% on day 5. In conclusion, our data suggest that an overexpression of ErbB-2 by cDNA transfection results in a reduced androgen-responsiveness of C-33 LNCaP cells.
Discussion
Loss of androgen-sensitivity is the most critical step of prostate cancer progression. Although this issue has drawn considerable attention for several decades, the molecular mechanism remains largely unknown, mainly due to the lack of appropriate experimental models. Our culture system is developed by continuously passaging LNCaP cells in medium containing regular FBS . In this cell model, dierent Additionally, a decreased cellular PAcP expression, which is observed in advanced-stage prostate carcinomas, is seen in androgen-unresponsive LNCaP subclones. Using this model system, in this communication, we identify two important processes linked to androgen-responsive growth. First, in prostate cells that exhibit androgen-responsive growth, a low level of tyrosine phosphorylation of ErbB-2 is maintained by the PTP activity of cellular PAcP. Second, in these cells, the induction of tyrosine phosphorylation on ErbB-2, which is at least in part due to a decrease of cellular PAcP, correlates with the androgen-promoted cell proliferation. Thus, results from our current studies suggest a crosstalk between androgen action and phosphotyrosine signaling, which works coordinately in executing the androgen-stimulation of prostate cell growth.
ErbB-2 protein is overexpressed in about 30% of human breast carcinomas, predominantly due to the ampli®cation of erbB-2/neu gene (Slamon et al., 1989; Harris et al., 1992; Press et al., 1993) . It has been shown that an overexpression of ErbB-2 can induce the focus formation and cell transformation, even in the absence of erbB ligands (Di Fiore et al., 1987; Hudziak et al., 1987; Bacus et al., 1996) . Further studies show that the level of ErbB-2 is clinically important and can be used as a prognostic marker of human breast cancers (Slamon et al., 1989; Hynes and Stern, 1994; Bacus et al., 1996) . Additionally, the ampli®cation of ErbB-2 may contribute to the loss of steroid hormonestimulated growth in that cancer. For instance, in MCF-7 cells overexpressing ErbB-2, the nuclear binding and retention of ER are enhanced, promoting the production of estrogen-induced proteins even in the absence of estrogen (Pietras et al., 1995) . Nevertheless, the estrogen-binding capacity is signi®cantly reduced in ErbB-2 transfected cells (Pietras et al., 1995) . It is also shown that the ER activity is regulated by ErbB-2-mediated tyrosine phosphorylation (Pietras et al., 1995) . Therefore, the ampli®ed ErbB-2 in breast cancer cells can at least in part substitute for estrogen signaling.
ErbB-2 protein is expressed in prostate cancer cells and xenografts (Robinson et al., 1996) . Studies using LNCaP cells as a model have demonstrated that ErbB-2 is essential for transducing heregulin (NDF) (Grasso 6 cells/T75¯ask. The methods for maintaining cell culture and androgen treatment were the same as described in Figure 3 . Cells were harvested after 72 h of treatment by 10 78 M of DHT. 1 mg of total lysates were reacted with speci®c Abs to precipitate EGFR and ErbB-3 proteins, which were further analysed by immunoblotting with anti-p-Tyr Ab (pY, top in a and b), subsequently with anti-EGFR Ab (bottom in a) and anti-ErbB-3 Ab (bottom in b), respectively. Arrows in b, two forms of immunoprecipitated ErbB-3. Ratio, the relative p-Tyr level of precipitated proteins. IP: immunoprecipitation. (c and d) Dierent sublines of prostate cancer cells were plated at a density of 1.2610 6 cells/T75¯ask. After exposed to DHT for 72 h, cells were harvested and total lysates were analysed by immunoblotting with anti-EGFR Ab. Results from LNCaP and PC-3 sublines were shown in c and d, respectively et al., 1997), and interleukin-6 (IL-6) signaling (Qiu et al., 1998) , leading to the activation of MAP kinases. It has been shown that the orthotopic injection of rat prostate cells overexpressing the oncogenic ErbB-2 induces tumor progression and metastasis in nude mice (Marengo et al., 1997) . These data support the hypothesis that the activation of ErbB-2 promotes the prostate carcinogenesis.
Results from a recent study using an ErbB-2-overexpressed LAPC-4 human prostate cancer model show that the AR signaling can be modulated by the ampli®cation of erbB-2 gene (Craft et al., 1999) . Thus, it is proposed that the hormone-independent growth of human prostate cancer cells is due to the overexpression of ErbB-2 (Craft et al., 1999 (Kuhn et al., 1993; Strohmeyer and Slamon, 1994; Gu et al., 1996) . In contrast, dierent subclones of LNCaP cells utilized in the present study exhibit dierent degrees of androgen-responsiveness but express similar amounts of AR and ErbB-2 proteins (Figure 1) . Additionally, in ErbB-2-activated C-81 LNCaP cells, AR is fully functional for the androgen action as indicated by a DHT-up-regulation of the mRNA expression of PSA , which is an androgen-dependent gene. This result suggests that in human prostate cancer, ErbB-2-mediated loss of androgen-promoted cell growth is not due to ampli®ed ErbB-2 substituting for the steroid hormone-receptor interaction, which is a mechanism of estrogenunresponsive phenotype in ErbB-2-ampli®ed human breast cancer (Pietras et al., 1995) . Nevertheless, the pTyr status of ErbB-2 is a key factor in determining the proliferation rate and androgen-responsiveness of prostate cancer cells (Figures 1 and 2) . Thus, data from our model provide the ®rst insight into the molecular mechanism by which the androgen-refractory stage of prostate cancer occurs.
Although the p-Tyr status of ErbB-2 is critical in determining androgen-responsiveness, the degree of androgen-promoted proliferation in prostate cells is apparently restricted by the level of endogenous AR proteins. PC-411, 7412 and 7416 transfectants, which express a marginal level of functional AR (Figure 2b ), exhibit ErbB-2 proteins with low tyrosine phosphorylation (Figure 2c ). Indeed the proliferation of these cells can be up-regulated by DHT-treatment (Figure 2a) . Nevertheless, their androgen-responsiveness is in a lower degree than C-33 LNCaP, LN-28 and LN-40 cells, which have signi®cant AR expression (Figure 1 ). Additionally, a slight growth stimulation by DHT in ErbB-2-cDNA transfectants is observed (Figure 7b) , apparently due to the limited transfection eciency of LNCaP cells. It has been reported that in C-33 LNCaP 6 cells/T75¯ask. Three days after plating, cells were starved in a medium containing 2% charcoal-treated FBS for two more days. 10 78 M of DHT and 0.5 mM of AG 879 were added into culture medium as indicated in the ®gure. ErbB-2 protein was precipitated after 72 h of exposure, then analysed by immunoblotting with anti-p-Tyr Ab (pY), and subsequently with anti-ErbB-2 Ab. Bottom, C-33 LNCaP cells were seeded in a 5% FBS-containing medium at a density of 2610 5 cells/well in six-well plates. Three days after plating, cells were maintained in a steroid-reduced culture medium for 2 days. 10 78 M DHT with various concentrations of AG 879, as shown in the ®gures, were added into medium. Cells were harvested and counted after 72 h of exposure. The relative cell number of the control sample without androgen was de®ned as 1. The data shown are the average of duplicated wells from two sets of independent experiments. Bar, the range of results from duplicate wells. (b) Top, C-33 LNCaP cells were plated, maintained and treated with DHT (10 78 M) and AG 1478 (0.5 mM) for 72 h by the method as described in a (top section). In addition to DHT, cells were also exposed to 10 mg/ml of EGF in the presence or absence of 0.5 mM AG 1478 for 16 h before harvesting, as shown in the ®gure. EGFR protein was precipitated and analysed by immunoblotting with anti-p-Tyr, and subsequently with anti-EGFR Ab. Bottom. C-33 LNCaP cells were seeded, and maintained as described in A (bottom section). Cells were treated with 10 78 M DHT plus various concentrations of AG 1478 for 72 h before harvested and counted. The data shown are the average of duplicated wells from two sets of independent experiments. Bar, the range of results from duplicate wells. *P50.01 versus the sample without DHT treatment (n=4). IP: immunoprecipitation cells, approximately 30% cells can be successfully transfected using lipofectamine as a vehicle to deliver expression vectors (Zelivianski et al., 1998) . Therefore, our data together indicate that although the p-Tyr of ErbB-2 is involved in transducing signals for androgenresponsiveness of prostate cells, the level of AR protein apparently plays a critical role in regulating the degree of androgen stimulation.
It has been known for decades that a decreased cellular PAcP level correlates with prostate carcinogenesis (Reif et al., 1973; Foti et al., 1977; Loor et al., 1981; Lin et al., 1998) . We and others have determined that PAcP exhibits a neutral PTP activity (Li et al., 1984; Clinton, 1986, 1988; Schneider et al., 1993) . Moreover, our studies revealed that cellular PAcP dephosphorylates ErbB-2 on tyrosine residues in prostate cancer cells (Lin and Meng, 1996; Meng and Lin, 1998) . These results are also consistent with the proposal that dephosphorylation of tyrosine residues in ErbB-2 by cellular PAcP is pivotal in maintaining a slow growth rate and androgen-responsiveness in normal prostate epithelial cells. In prostate carcinomas, cellular PAcP expression is suppressed and ErbB-2 is constitutively tyrosine hyper-phosphorylated (Figures 1  and 2) , which leads to the activation of MAP kinase in clinical archival prostate tumor specimens (Gioeli et al., 1999) . Interestingly, we also observed that DHT Figure 7 Eect of overexpressed ErbB-2 on androgen-induced growth stimulation. C-33 LNCaP cells were seeded at a density of 2610 5 cells/well in six-well plates for transient transfection with pc3.1A (labeled as 3.1A), or pc3.1A-ErbB-2-Myc (labeled as ErbB-2) vector. Six hours after transfection, cells were cultured in a phenol red-free medium supplemented with 10% charcoal-treated FBS for overnight, and subsequently in the same medium containing 5% charcoal-treated FBS for additional 24 h. A set of transfectant samples, labeled as day 0 in the ®gure, were harvested, counted and lysed. Media with or without 10 78 M DHT were then added to the remaining cultures. Cells were counted and lysed on day 3 and day 5, while 3 ml/well fresh medium with or without DHT was added to the remaining wells on day 3. (a) Total lysates isolated on days 0, 3 and 5 were analysed by immunoblotting with anti-pTyr (pY), anti-Myc tag and anti-ErbB-2 Abs, respectively. Markers of 200 and 116 kDa positions on SDS-gels are labeled. Arrow, the position of pp185. (b) Results of relative cell counting at dierent time points. The number of pc3.1A vector-transfected cells at day 0 was de®ned as 1. The data shown are the average of duplicated wells. Two sets of independent experiments with similar results were seen. Bar, the range of results from duplicate wells can down-regulate the cellular level of exogenous PAcP in LN-28 and LN-40 cells since these expressions are driven by a CMV promoter (Figure 3a) . Our current results indicate that DHT down regulation of cellular PAcP may not be due to a direct DHT eect on the ARE of PAcP promoter (Figure 3a) . Rather, this DHT eect may be via PKC signaling (Lin et al., 2000) . The molecular mechanism would require further studies.
EGFR is proposed to be a mediator of androgeninduced proliferation signals. (Schuurmans et al., 1991; Liu et al., 1993; Brass et al., 1995; Sherwood et al., 1998) . However, our studies ( Figure 5 ) and Sherwood's studies (Sherwood et al., 1998) have shown that in human prostate cells, androgen does not consistently up-regulate EGFR and TGF-a, an endogenous ligand of EGFR. Utilizing speci®c inhibitors of RTKs, our studies further demonstrate that the androgen signal pathway bypasses EGFR (Figure 6 ). To the best of our knowledge, this is the ®rst report to clearly exclude EGFR from androgen actions on cell proliferation. Nevertheless, the expression of EGFR as well as AR in LN-28 and LN-40 cells is decreased (Figure 1b) . The decreased expression may be due to the exogenous PAcP expression that down regulates the cellular growth, which leads to a decrease in EGFR and AR protein levels. Alternatively, the decreased EGFR and AR protein levels may be due to the clonal heterogeneity of subcloned cells. Interestingly, we observed that in C-33 LNCaP and PC-3 cells, DHT up-regulated EGFR level (Figure 5c,d) . The eect of DHT on the expression of EGFR may be by decreasing PAcP expression, leading to an increased c-ErbB-2 signaling which, in turn, up-regulates the AR transactivation activity (Yeh et al., 1999) resulting in the expression of EGFR. Alternatively, it is possible that the AR-DHT complex can directly enhance the expression of EGFR. The molecular mechanism requires further studies. It is also observed that ErbB-3 has a low tyrosine phosphorylation level in androgen-sensitive LNCaP sublines (Figure 1 ). Since its phosphorylation status is not regulated by androgen (Figure 5b ) and since it also has an impaired tyrosine kinase activity (Guy et al., 1994) , ErbB-3 may not play a critical role in the steroid hormone-induced signaling pathway in prostate cells.
Dimerization between dierent erbB receptors is thought to be responsible for the ligand-induced cross-phosphorylation (Plowman et al., 1993; Sliwkowski et al., 1994; Beerli and Hynes, 1996) . NDF and IL-6 can induce heterodimerization between ErbB-2 and ErbB-3, which results in their increased tyrosine phosphorylation in prostate cancer cells (Grasso et al., 1997; Qiu et al., 1998) . Similarly, EGF induces , and the other pathway to activate ErbB-2-speci®c tyrosine kinases () in PAcP-expressing cells. Tyrosines phosphorylated ErbB-2 proteins form homodimers, and subsequently activate downstream MAP kinase signaling pathway, leading to a rapid growth rate formation of heterodimers of EGFR-ErbB-2 in various cell lines (Beerli and Hynes, 1996; Riese et al., 1996) . Homodimerization of ErbB-2 receptors, however, has also been reported to be sucient for the constitutive activation of proliferation and transformation signals (Di Fiore et al., 1987; Hudziak et al., 1987; Bacus et al., 1996) . In the current study, it is clear that androgen cannot induce heterodimerization between ErbB-2 and EGFR, or between ErbB-2 and ErbB-3, since we do not observe an increased p-Tyr level on either EGFR or ErbB-3 by DHT ( Figure 5 ). We therefore hypothesize that ErbB-2 proteins only form homodimers in cells treated with DHT. Apparently androgen action only aects intracellular p-Tyr signaling pathways but cannot in¯uence the autocrine loop of EGFR or ErbB-3. However, further experiments are needed to determine the exact mechanism.
Time course studies of androgen treatment demonstrate that the decreased PAcP expression and the activation of ErbB-2 is not an early event in growth stimulation of LNCaP cells (Figure 4) . A period of 24 h is apparently required to down-regulate the expression of cellular PAcP. However, we did not observe an immediate induction of p-Tyr level on ErbB-2 at this time point. An increase of p-Tyr level on ErbB-2 appears after 48 h of exposure to androgen in C-33 LNCaP cells (Figure 4a ). This delayed response of ErbB-2, however, cannot explain the initial stimulation of androgen-promoted cell proliferation (Lin et al., 1992; Lu et al., 1997) . Thus, other signal pathways are responsible for mediating the immediate eects of androgen treatment. For example, when LNCaP cells are exposed to DHT, cyclin-dependent kinase (CDK)-2 and -4 at mRNA and protein levels are up-regulated within 8 h (Lu et al., 1997) . Within 24 h, androgen suppresses the expression of CDK inhibitor p16 (Lu et al., 1997) . The overall activity of CDKs, therefore, is increased resulting in progression of cells to enter the S phase of the cell cycle. Nevertheless, we propose that ErbB-2 is the key factor to determine the onset of androgen action on the exponential growth phase, which occurs after 48 h of treatment in LNCaP cells (Lu et al., 1997) , corresponding to the time point at which ErbB-2 is highly tyrosine phosphorylated (Figure 4a ).
Our proposed model as illustrated in Figure 8 summarizes a network of events by which androgen action on cell proliferation is proceeded in human prostate cells. The data suggest that expression of cellular PAcP is important to maintain a slow growth rate and to preserve androgen sensitivity by dephosphorylating ErbB-2 on tyrosine residues (Figure 8a ). In the presence of androgen, AR is activated that leads to a stimulation or a suppression of transcriptional process of targeting genes (Beato, 1989; Horwitz, 1992; Kallio et al., 1994) . The alteration of gene expression including down-regulation of cellular PAcP expression through a yet unidenti®ed mechanism, resulting in a constitutively tyrosine phosphorylated ErbB-2 protein (Figure 8b ). Our preliminary results in time-kinetic studies show that in androgen-treated C-33 LNCaP cell lysates, several cellular proteins are hyper-tyrosine phosphorylated prior to the activation of ErbB-2 (data not shown). Thus, it is possible that other androgen amenable tyrosine kinase(s) that can phosphorylate ErbB-2 is stimulated; by which the p-Tyr level of ErbB-2 is further elevated (Figure 8b ). Subsequently, proliferation signaling pathways downstream of ErbB-2 are induced, leading to the activation of MAP kinases (Figure 8b ) (Yeh et al., 1999) . In advanced prostate cancer cells including C-81 LNCaP and PC-3 cells, the lack of cellular PAcP expression results in a constitutively tyrosine phosphorylated ErbB-2, leading to a rapid cell growth rate and a hormone-refractory phenotype. Although androgen can still activate the transcriptional machinery in these cells, this steroid hormone has no additional eect on the tyrosine phosphorylation of ErbB-2. In conclusion, our date clearly show the signaling pathway of androgen action mediated by the interaction of cellular PAcP with ErbB-2 protein in prostate cells. This pathway illustrates one of the common mechanisms by which androgen-responsiveness is attenuated in the advanced-stage prostate cancer cells. This information not only delineates the molecular interaction between PTP and PTK in regulating steroid hormone action on cell proliferation, but also lights up possible therapeutic approaches for hormone-refractory prostate cancers.
Materials and methods

Materials
Fetal bovine serum (FBS), cell culture medium, gentamycin, Lipofectamine Plus reagents for transfection, horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgGs were purchased from Life Technologies, Inc (Grand Island, NY, USA). Charcoal/Dextran-treated, certi®ed FBS (lot # AGD6463, testosterone53.0 ng/dl) was from Hyclone (Logan, UT, USA). Protein molecular weight standard marker, acrylamide, and protein assay kit were obtained from BioRad (Hercules, CA, USA). Vectors pGEM-9zf(7), and pcDNA3.1(7)/Myc-His A, B, C were from Promega (Madison, WI, USA), and Invitrogen (Carlsbad, CA, USA), respectively. Plasmid pCMV-HER2 was a kind gift from Dr Hsing-Jien Kung in the University of California at Davis. Polyclonal anti-EGFR (1005), anti-ErbB-2 (C-18 and K-15), anti-ErbB-3 (C-17) and anti-MAP kinase (K-23) antibodies (Abs), monoclonal anti-EGFR (R-1) and anti-ErbB-2 (9G6) Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal anti-phospho-MAP kinase (9101S) Ab was purchased from New England Biolabs (Beverly, MA, USA). Rabbit anti-PAcP antiserum was obtained as described previously (Lin et al., 1993) . NH-27 rabbit anti-AR antiserum was described before . Monoclonal anti-p-Tyr antibody (4G10) was from UBI (Lake Placid, NY, USA). Anti-Myc tag monoclonal antibody (Evan et al, 1985) was a generous gift from Dr Robert Lewis at the Eppley Cancer Institute, University of Nebraska Medical Center. Tyrphostins AG 897 and AG 1478 were obtained from Calbiochem (San Diego, CA, USA). Restriction enzymes were from Life Technologies, New England Biolabs, and Promega. Enhanced chemiluminescence (ECL) detection system was purchased from Amersham Life Science, Inc (Arlington Height, IL, USA). All other reagents were from Sigma (St Louis, MO, USA).
Cell culture
Human prostate cancer cell lines LNCaP, DU 145, and PC-3 were originally obtained from American Type Culture Collection (Rockville, MD, USA), and routinely maintained in RPMI 1640 medium supplemented with 5% FBS, 1% glutamine and 0.5% gentamicin. Cells were split once per week de®ned as one passage. LNCaP cells that had passage numbers less than 33 were designated as C-33, greater than 80 as C-81, between 34 and 80 as C-51 Meng and Lin, 1998) . To determine the androgen eect, cells were seeded at the density of 2610 4 cells/cm 2 and maintained in the medium with 5% FBS for 3 days. Cells were further incubated in a phenol red-free RPMI 1640 medium containing 2% charcoal-treated, heat-inactivated FBS for additional 48 h before DHT treatment. After a time period speci®ed in each set of experiments, cells were harvested and counted using a Coulter Counter for cell growth studies or lysed as described below.
Stable transfectants with PAcP expression vector
C-81 LNCaP cells were transfected with a full length human PAcP cDNA driven by a pCMV-neo expression vector, as described previously Meng and Lin, 1998) . Two subclones designated as LNCaP-28 and -40 were obtained as the stable transfectants after neomycin selection. LNCaP-CMV is a subline of LNCaP C-81 cells transfected with the pCMV-neo vector alone. PC-411, -412, and -416 cells were subclones of PC-3 parental cells transfected with the same expression vector containing human PAcP cDNA (Lin et al., 1992; Meng and Lin, 1998) .
Construction of a Myc-His-tagged ErbB-2 expression vector and transient transfection
The full length cDNA of c-erbB-2 was released from a CMV-HER2 plasmid by HindIII enzyme, then inserted into a pGEM-9zf(7) vector as the template (pGEM-9-HER2) for further polymerase chain reactions (PCRs), which remove the endogenous stop codon and make c-erbB-2 cDNA sequence in-frame for expressing a Myc-His-tagged protein in cells. A PCR fragment that replaces a 0.7 kb stretch proximal to the 3' end of c-erbB-2 cDNA was ampli®ed using two oligonucleotide primers: 5'-TATCTGGTACCCCAG-CAGGGCTT-3' (KpnI site is underlined) and 5'-GTTCTA-GAAGCTTCACTGGCACGTCCAGACCCA-3' (XbaI and HindIII sites are underlined). Both pGEM-9-HER2 plasmid and PCR fragment were reacted with restriction enzymes XbaI and KpnI before the ligation was conducted. The ligated plasmid designated pGEM-9-HER2-PCR contains the fulllength coding region of c-erbB-2 without the endogenous stop codon. The sequence of PCR product was con®rmed using two primers for the sequencing reaction: 5'-CAGATC-CTCTTCTGAGATGAG-3' and 5'-ACCTGGTGGATGCT-GAGGAGTA-3'. The vector pGEM-9-HER2-PCR was then digested by HindIII enzyme to release the insert, which was further ligated with a HindIII-cut pc3.1A vector. The ligated product, designated as pc3.1A-HER2-Myc, is a CMV promoter-driven expression vector that expresses ErbB-2 protein tagged with the Myc and 6 x His epitopes on its Cterminus.
For transient transfection, C-33 LNCaP cells were plated at the densities of 2.0610 5 cells/well in a 6-well plate, or 1610 6 cells/dish in a 100 mm petri dish. Forty-eight hours after plating in RPMI 1640 medium containing 5% FBS, 1 mg/well or 5 mg/dish of plasmid DNA was introduced into LNCaP cells by complexing with Lipofectamine reagent as described in the commercial protocol. After 6 h of incubation, the culture medium was replaced by RPMI 1640 containing 10% FBS, and incubated for an additional 16 h. Cells were then maintained as described in each speci®c experiment.
Immunoprecipitation and immunoblotting
Subcon¯uent cells were harvested and lysed as described previously . Brie¯y, cells were pelleted and rinsed with ice-cold HEPES-buered saline, pH 7.0, then lysed in ice-cold cell lysis buer containing protease and phosphatase inhibitors. The lysates were spun, the supernatants were recovered and the protein concentration was determined using the Bio-Rad protein assay kit. For immunoprecipitation, 1 mg of supernatant protein was incubated with antibody-conjugated Protein A-Sepharose complex for 2 h at 48C. The immunocomplexes were spun, washed four times with ice-cold lysis buer, and suspended in SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) sample buer. For immunoblotting, an aliquot of total lysate protein (30 mg), or the supernatant of immunoprecipitated complexes in SDS ± PAGE sample buer was electrophoresed, transferred to nitrocellulose ®lters (Micron Separation Inc, MA, USA). Filters were incubated with appropriate primary antibody in TBST buer (Tris-buered Saline, pH 7.5 containing 0.1% Tween-20) containing 5% dry skim milk for 3 h, subsequently with secondary antibody in TBST buer for 1 h. The protein bands were visualized by the ECL detection system. For reprobing, ®lters were agitated with the stripping buer for 30 min at 508C. After two washes with TBST buer, the ®lters were reacted with speci®c antibodies and the signal was detected by the ECL method.
